EXEL
Exelixis
$55.07
▲ +3.85%
+$2.04
NYSE · Healthcare · Biotechnology
· price updated 9h ago
Exelixis
EXEL · NYSE · Healthcare · Biotechnology · price updated 9h ago
$55.07
▲ +3.85% · +$2.04 today
AI research · $55.07
Track EXEL for continuous AI research
price position
Where EXEL sits now
52-week range
Low$33.76
High$57.57
Today $55.07
RSI (14)
40.7Neutral
03070100
fundamentals
Business quality and valuation
Operating record
What the business has actually produced
Revenue
Capital structure
Cash versus debt
Cash & investments$777.2M
Total debt$169.5M
Net cash after debt$607.7M
Valuation
What the market charges
Forward P/E
Price against expected earnings
Favorable · 23% below Sector avg · favorable
16.09x
Price / sales
Value assigned to each sales dollar
Reasonable · Between 3x and 8x sales
5.61x
Price / FCF
Price against free cash generation
Strong · Under 20x free cash flow
14.52x
EV / EBITDA
Operating value including debt
Reasonable · Between 12x and 22x EBITDA
12.51x
Quality
How efficiently it compounds
ROIC
Return earned on invested capital
Strong · At least 15% return on capital
60.4%
ROE
Profit generated from shareholder equity
Favorable · Exceptional vs sector peers
41.0%
Debt / equity
Balance-sheet leverage
Favorable · Exceptional vs sector peers
0.09x
Current ratio
Short-term assets against liabilities
Strong · Comfortable short-term liquidity
3.26x
Geographic mix
Mar 31, 2026United States91.8% · $2.2B
Europe6.8% · $161.0M
Japan1.4% · $32.7M
Selected financial data sourced from StockAnalysis and refreshed weekly. Figures may be delayed and are for research context, not investment advice.
peer comparison
How EXEL compares
| company | mkt cap | P/E | rev growth | score |
|---|---|---|---|---|
| $13.33B | 17.6 | +3.3% | 69 |
 | $10.69B | 18.4 | +23.5% | 78 |
 | $4.88B | 20.3 | +10.3% | 77 |
 | $31.49B | 32.9 | +15.5% | 77 |
 | $1.08T | 41.4 | +47.4% | 76 |
US stock research
About Exelixis (EXEL) stock
Exelixis tracked in the US core universe. EXEL was +3.9% in the latest available session at $55.07. Its reported market value was $13.33B with a trailing P/E of 17.6. Latest reported revenue was $2.38B, changing +3.3% year over year, with $833.42M in net income.
Market snapshot updated Aug 3, 2026, 7:59 PM UTC.
- Latest available price
- $55.07
- Day change
- +3.9%
- Market cap
- $13.33B
- P/E (TTM)
- 17.6
- Revenue growth
- +3.3%
- Industry
- Biotechnology